NO20053304L - NOGO A bindingsmolekyler og farmasoytisk anvendelse av disse - Google Patents

NOGO A bindingsmolekyler og farmasoytisk anvendelse av disse

Info

Publication number
NO20053304L
NO20053304L NO20053304A NO20053304A NO20053304L NO 20053304 L NO20053304 L NO 20053304L NO 20053304 A NO20053304 A NO 20053304A NO 20053304 A NO20053304 A NO 20053304A NO 20053304 L NO20053304 L NO 20053304L
Authority
NO
Norway
Prior art keywords
human
nogo
binding molecule
binding molecules
pharmaceutical use
Prior art date
Application number
NO20053304A
Other languages
English (en)
Norwegian (no)
Other versions
NO20053304D0 (no
Inventor
Martin E Schwab
Carmen Barske
Anis Khusro Mir
Thomas Oertle
Lisa Schnell
Alessandra Vitaliti
Mauro Zurini
Original Assignee
Univ Zuerich Prorektorat Forsc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Zuerich Prorektorat Forsc filed Critical Univ Zuerich Prorektorat Forsc
Publication of NO20053304D0 publication Critical patent/NO20053304D0/no
Publication of NO20053304L publication Critical patent/NO20053304L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
NO20053304A 2002-12-10 2005-07-06 NOGO A bindingsmolekyler og farmasoytisk anvendelse av disse NO20053304L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0228832.2A GB0228832D0 (en) 2002-12-10 2002-12-10 Organic compound
PCT/EP2003/013960 WO2004052932A2 (en) 2002-12-10 2003-12-09 Antibody (“11c7”) anti nogo a and its pharmaceutical use

Publications (2)

Publication Number Publication Date
NO20053304D0 NO20053304D0 (no) 2005-07-06
NO20053304L true NO20053304L (no) 2005-09-07

Family

ID=9949456

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20053304A NO20053304L (no) 2002-12-10 2005-07-06 NOGO A bindingsmolekyler og farmasoytisk anvendelse av disse

Country Status (24)

Country Link
US (2) US7785593B2 (de)
EP (1) EP1572745B1 (de)
JP (1) JP4504200B2 (de)
KR (1) KR101215801B1 (de)
CN (1) CN100384877C (de)
AT (1) ATE475671T1 (de)
AU (1) AU2003289998B2 (de)
BR (1) BR0317161A (de)
CA (1) CA2509068C (de)
CY (1) CY1110848T1 (de)
DE (1) DE60333585D1 (de)
DK (1) DK1572745T3 (de)
EC (1) ECSP055849A (de)
ES (1) ES2349293T3 (de)
GB (1) GB0228832D0 (de)
IL (1) IL169018A (de)
MX (1) MXPA05006265A (de)
NO (1) NO20053304L (de)
PL (1) PL210720B1 (de)
PT (1) PT1572745E (de)
RU (1) RU2350623C2 (de)
SI (1) SI1572745T1 (de)
WO (1) WO2004052932A2 (de)
ZA (1) ZA200504522B (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0228832D0 (en) 2002-12-10 2003-01-15 Novartis Ag Organic compound
GB0321997D0 (en) * 2003-09-19 2003-10-22 Novartis Ag Organic compound
US7988964B2 (en) * 2003-12-22 2011-08-02 Glaxo Group Limited NOGO-a neutralising immunoglobulin for treatment of neurological diseases
HRP20120851T1 (hr) * 2005-07-05 2012-11-30 Glaxo Group Limited Humanizirana protutijela specifiäśna za nogo-a i njihova farmaceutska upotreba
GB0525662D0 (en) 2005-12-16 2006-01-25 Glaxo Group Ltd Immunoglobulins
AU2008317724B2 (en) 2007-11-02 2011-06-02 Novartis Ag Improved Nogo-A binding molecules and pharmaceutical use thereof
WO2010004031A2 (en) * 2008-07-11 2010-01-14 Glaxo Group Limited Novel treatment
US8828390B2 (en) 2010-07-09 2014-09-09 Universitat Zurich Uses of NOGO-A inhibitors and related methods
IN2014KN02952A (de) 2012-07-05 2015-05-08 Glaxo Group Ltd
US9534044B2 (en) * 2013-02-28 2017-01-03 United Arab Emirates University Alpha-synuclein antibodies and uses thereof
JP6604942B2 (ja) * 2013-06-13 2019-11-13 バイオマトリカ，インク． 細胞安定化
KR20250065434A (ko) 2016-03-01 2025-05-12 이섬 리서치 디벨러프먼트 컴파니 오브 더 히브루 유니버시티 오브 예루살렘 엘티디. 인간 폴리오바이러스 수용체(ｐｖｒ)에 특이적인 항체
EP4041392A1 (de) 2019-10-08 2022-08-17 Nectin Therapeutics Ltd. Antikörper gegen den poliovirus-rezeptor (pvr) und verwendungen davon
WO2021079002A2 (en) * 2019-10-24 2021-04-29 Novago Therapeutics Ag Novel anti-nogo-a antibodies
WO2026041734A1 (en) 2024-08-22 2026-02-26 Novago Therapeutics Ag Methods for treating neurological disorders using anti-nogo-a antibodies

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308573D0 (en) 1983-03-29 1983-05-05 British Nuclear Fuels Ltd Filament impregnating/coating
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
WO1988001649A1 (en) 1986-09-02 1988-03-10 Genex Corporation Single polypeptide chain binding molecules
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5180820A (en) * 1989-08-30 1993-01-19 Barde Yves Alain Brain-derived neurotrophic factor
SK281143B6 (sk) * 1991-03-06 2000-12-11 Merck Patent Gesellschaft Mit Beschr�Nkter Haftung Chimérická monoklonálna protilátka, expresné vektory a farmaceutický prostriedok
DE69942803D1 (de) 1998-07-22 2010-11-11 Smithkline Beecham Ltd Rotein änhelt, und dafür kodierende cdns
WO2000031235A2 (en) 1998-11-06 2000-06-02 Schwab Martin E Nucleotide and protein sequences of nogo genes and methods based thereon
CU22921A1 (es) * 1999-11-16 2004-02-20 Centro Inmunologia Molecular Anticuerpos quimérico, humanizado y el fragmento de tipo fv de cadena sencilla que reconoce el antígeno c2. su uso en el diagnóstico y tratamiento de tumores colorrectales
HUP0203863A3 (en) * 2000-01-12 2008-03-28 Univ Yale Nogo receptor-mediated blockade of axonal growth
ES2318006T3 (es) * 2001-04-30 2009-05-01 Eli Lilly And Company Anticuerpos humanizados que reconocen el peptido beta-amiloide.
DE20110806U1 (de) 2001-06-29 2001-12-20 Jack Wolfskin Ausrüstung für Draussen GmbH, 65510 Idstein Zelt
AU2002357770B2 (en) * 2001-11-30 2008-07-31 Biogen Ma Inc. Antibodies against monocyte chemotactic proteins
GB0228832D0 (en) 2002-12-10 2003-01-15 Novartis Ag Organic compound
US7988964B2 (en) * 2003-12-22 2011-08-02 Glaxo Group Limited NOGO-a neutralising immunoglobulin for treatment of neurological diseases
US7596225B2 (en) * 2005-06-30 2009-09-29 Alcatl-Lucent Usa Inc. Method for refreshing a pairwise master key

Also Published As

Publication number Publication date
KR20050095768A (ko) 2005-09-30
PL210720B1 (pl) 2012-02-29
CY1110848T1 (el) 2015-06-10
US20060183678A1 (en) 2006-08-17
EP1572745B1 (de) 2010-07-28
HK1084676A1 (en) 2006-08-04
AU2003289998B2 (en) 2008-02-14
CN1747971A (zh) 2006-03-15
WO2004052932A3 (en) 2004-10-21
NO20053304D0 (no) 2005-07-06
US7785593B2 (en) 2010-08-31
IL169018A (en) 2012-07-31
EP1572745A2 (de) 2005-09-14
US20110059110A1 (en) 2011-03-10
JP4504200B2 (ja) 2010-07-14
RU2005121669A (ru) 2007-01-20
AU2003289998A1 (en) 2004-06-30
WO2004052932A2 (en) 2004-06-24
SI1572745T1 (sl) 2010-12-31
CA2509068C (en) 2012-02-07
PL377506A1 (pl) 2006-02-06
DK1572745T3 (da) 2010-10-25
ECSP055849A (es) 2005-09-20
GB0228832D0 (en) 2003-01-15
CN100384877C (zh) 2008-04-30
US8535666B2 (en) 2013-09-17
ZA200504522B (en) 2006-03-29
CA2509068A1 (en) 2004-06-24
KR101215801B1 (ko) 2012-12-26
PT1572745E (pt) 2010-10-21
ATE475671T1 (de) 2010-08-15
MXPA05006265A (es) 2005-12-05
RU2350623C2 (ru) 2009-03-27
BR0317161A (pt) 2005-11-01
JP2006523087A (ja) 2006-10-12
DE60333585D1 (de) 2010-09-09
ES2349293T3 (es) 2010-12-29

Similar Documents

Publication Publication Date Title
CY1110848T1 (el) Αντισωμα αντι ανθρωπου νοgo α kai h φαρμακευτικη του χρηση
ECSP056263A (es) Anticuerpos humanizados que reconocen el péptido beta amiloideo
ATE416190T1 (de) Polypeptide mit bindungsaffinität für her2
CY1117387T1 (el) ΜΟΝΟΚΛΩΝΙΚΑ ΑΝΤΙΣΩΜΑΤΑ Ν-11 ΔΙΑΣΠΑΣΜΕΝΟΥ β-ΑΜΥΛΟΕΙΔΟΥΣ, ΣΥΝΘΕΣΕΙΣ, ΜΕΘΟΔΟΙ ΚΑΙ ΧΡΗΣΕΙΣ
MX2009013824A (es) Proteinas de enlace de antigeno que enlazan par-2.
ATE492563T1 (de) Vollständige humane monoklonale antikörper gegen il-13
EA200700136A1 (ru) Анти-cd154-антитела
CY1115920T1 (el) Αντι-gm-csf αντισωματα και χρησεις αυτων
BRPI0715660B8 (pt) anticorpo isolado que se liga a il-31 humana, e, uso de um anticorpo monoclonal
ATE506072T1 (de) Immunogene und entsprechende antikörper, die spezifisch sind für häufige hochmolekulare aggregations-zwischenprodukte von amyloiden aus proteinen unterschiedlicher sequenz
DE602004016499D1 (de) Zusammensetzungen und verfahren zur behandlung von entzündlicher darmerkrankung
TW200635946A (en) Binding proteins specific for human matriptase
DE69931482D1 (de) Isolierte peptide die aminosäuresequenzen von ny-eso-1 entsprechen und an mhc-klasse i und mhc klasse ii moleküle binden, und deren verwendungen
PE20021098A1 (es) ANTICUERPOS ESPECIFICOS DE CD44v6
DE60228504D1 (de) P53 bindende t-zellrezeptormoleküle und deren verwendungen
WO2006083964A3 (en) Modified fusion molecules for treatment of allergic disease
PE20090981A1 (es) Moleculas aglutinantes de nogo-a mejoradas y uso farmaceutico de las mismas
BRPI0407031A (pt) Composições e métodos para tratamento de câncer empregando igsf9 e liv-1
WO2007039256A3 (de) Bindungsdomänen von proteinen der repulsive guidance molecule (rgm) proteinfamilie und funktionale fragmente davon sowie deren verwendung
PE20250753A1 (es) Inmunoconjugados de il-2 atenuada-anticuerpo anti-pd-1 y usos de los mismos
BRPI0414174B8 (pt) anticorpos ou fragmentos de ligação a antígeno do mesmo uso dos mesmos, polinucleotídeo, vetor, sistema de expressão, e composição farmacêutica.
SE0301987D0 (sv) New polypeptide
DE602006020333D1 (de) Multimere fc-rezeptor-polypeptide
Cozma Determination of Primary Structure and Affinity Characterization of Naturally Occurring β-Amyloid Autoantibodies

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application